CD19 Protein

Catalog No. ABIN2746374

This Recombinant CD19 protein is produced in Escherichia coli (E. coli).

Quick Overview for CD19 Protein (ABIN2746374)

Target: CD19 (CD19 Molecule (CD19))

Protein Type: Recombinant

Origin: Human, Mouse, Rat

Source: Escherichia coli (E. coli)

Application: Western Blotting (WB), Positive Control (PC)

Product Details

Purpose: Purified Protein in ready-to-use SDS sample buffer.

Specificity: The antibody labels a strong band of CD19 at 67 kDa in ABIN1741617 samples and in other cancer cell lines.

Purification: Purified Protein

Application Details

Application Notes: The sample is in ready-to-use buffer for application in SDS-PAGE and Western blotting.

Comment:

Synonyms: B-lymphocyte surface antigen B4, Differentiation antigen CD19, T-cell surface antigen Leu-12, CD_antigen=CD19, B lymphocyte antigen CD19, B lymphocyte surface antigen B4 antibody, Leu12 antibody, Lymphocyte Surface Antigen antibody, MGC109570 antibody, MGC12802 antibody, T-cell surface antigen Leu-12 antibody.

Restrictions: For Research Use only

Handling

Format: Liquid

Buffer: For 5 applications, volume varies from 100-200 μL in reduced SDS-PAGE sample buffer.

Storage: -20 °C

Storage Comment: -20 °C for long term storage

Target Details

Target: CD19 (CD19 Molecule (CD19))

Alternative Name: CD19

Background: CD19 (Cluster of Differentiation 19) also known as B4, is a 95 kDa type-I transmembrane glycoprotein which is restricted to B cell antigen. CD19 is a cell surface molecule which assembles with the antigen receptor of B lymphocytes in order to decrease the threshold for antigen receptor-dependent stimulation. It contains two extracellular immunoglobulin-like domains and is selectively expressed on the cell surface of B-lymphocytes, where it activates intracellular signaling cascades. CD19 antigen is also found on the follicular dendritic cells and the early cells of myelomonocytic lineage but not on normal T cells, NK cells, monocytes, granulocytes, erythrocytes and platelets. In normal peripheral blood, 8-20 % of lymphocytes express CD19 antigen, but plasma cells do not express this antigen. CD19 antigen plays a role in regulating B cell proliferation.The cytoplasmic tail of CD19 has nine conserved tyrosine residues playing critical roles in CD19 mediated function by coupling signaling molecules to the receptor. After B cell receptor or CD19 ligation, Tyr531 and Tyr500 of CD19 are progressively phosphorylated. The phosphorylation at these sites mediates elevated intracellular calcium response, as well as the JNK pathway. Defects in CD19 causes common variable immunodeficiency type 3 (CVID3) also called antibody deficiency due to CD19 defect. CVID3 is characterized by hypogammaglobulinemia, recurrent bacterial infections and an inability to mount an antibody response to antigen. The defect results from a failure of B-cell differentiation and impaired secretion of immunoglobulins. Adoptive T-cell therapy with CD19-specific chimeric antigen receptors (CARs) is promising for treatment of advanced B-cell malignancies. CD19-CAR T-cells enhance the efficacy of adoptive T-cell therapy for refractory B-cell lymphoma. The human CD19 gene maps to chromosome 16p11.2 and encodes a 557 amino acid protein.

Molecular Weight: 76 kDa

UniProt: P15391

Pathways: Fc-epsilon Receptor Signaling Pathway, EGFR Signaling Pathway, Neurotrophin Signaling Pathway